Data From PREVAIL Trial of Enzalutamide in Chemotherapy-Naive Metastatic Prostate Cancer to Be Presented in Late-Breaking Ses...
Print
Alert
Medivation, Inc. (MM) (NASDAQ:MDVN)
Intraday Stock Chart
Today : Thursday 19 December 2013
Click Here for more Medivation, Inc. (MM) Charts. Data From PREVAIL Trial of Enzalutamide in Chemotherapy-Naive Metastatic Prostate Cancer to Be Presented in Late-Breaking Session at ASCO GU Symposium
ASCO GU Names Abstract Among Four to Be Highlighted During 2014 Meeting
SAN FRANCISCO, CA and NORTHBROOK, IL--(Marketwired - Dec 19, 2013) - Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Global Development, Inc. announced that additional data from the Phase 3 PREVAIL trial evaluating enzalutamide in patients with chemotherapy-naïve metastatic prostate cancer will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology (ASCO) 2014 Genitourinary (GU) Cancers Symposium in San Francisco.
Details of the oral presentation are as follows:
Title: Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of Phase 3 PREVAIL Study
Presenter: Tomasz M. Beer, OHSU Knight Cancer Institute, Oregon Health & Science University
•Session Detail: Welcome and General Session 1: Integrating Androgen Axis Therapy across the Disease Spectrum
•Session Date/Time: January 30, 2014 from 7:45 a.m - 9:45 a.m.
Two additional enzalutamide abstracts will be presented during General Poster Sessions:
•(Abstract #62) Enzalutamide monotherapy: Phase 2 study results in hormone-naïve prostate cancer patients. Presenter: Bertrand Tombal, Université Catholique de Louvain, Cliniques Universitaires Saint-Luc (11:30 a.m. - 1:00 p.m., Thursday, January 30, 2014)
•(Abstract #247) Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone. Presenter: Mark Creamer Scholz, Prostate Oncology Specialists (12:00 - 1:30 p.m., Friday, January 31, 2014)
